{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T07:19:25Z","timestamp":1781421565083,"version":"3.54.1"},"reference-count":32,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1080\/10401230590932326","type":"journal-article","created":{"date-parts":[[2006,2,21]],"date-time":"2006-02-21T11:26:34Z","timestamp":1140521194000},"page":"65-69","source":"Crossref","is-referenced-by-count":79,"title":["A Double-Blind Comparison of Escitalopram and Paroxetine in the Long-Term Treatment of Generalized Anxiety Disorder"],"prefix":"10.1177","volume":"17","author":[{"given":"Robert J.","family":"Bielski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Chi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2005,4]]},"reference":[{"key":"E00001","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1176\/appi.ajp.160.4.749","volume":"160","author":"Rickels K","year":"2003","unstructured":"Rickels, K and Zaninelli, R and McCafferty, J and Bellew, K and Iyengar, M and Sheehan, D. (2003) Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study Am J Psychiatry<\/i>, 160, pp. 749 - 756. [PUBMED]<\/a>[INFOTRIEVE]<\/a>[CROSSREF]<\/a>","journal-title":"Am J Psychiatry"},{"key":"E00002","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4088\/JCP.v64n0305","volume":"64","author":"Stocchi F","year":"2003","unstructured":"Stocchi, F and Nordera, G and Jokinen, RH and Lepola, UM and Hewett, K and Bryson, H and Iyengar, MK. (2003) Paroxetine Generalized Anxiety Disorder Study Team: Paroxetine Generalized Anxiety Disorder Study Team. 2003. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder J Clin Psychiatry<\/i>, 64, pp. 250 - 258. [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"J Clin Psychiatry"},{"key":"E00003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0091-3057(01)00701-8","volume":"71","author":"Brocco M","year":"2002","unstructured":"Brocco, M and Dekeyne, A and Veiga, S and Girardon, S and Millan, MJ. (2002) Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents Pharmacol Biochem Behav<\/i>, 71, pp. 667 - 680. [PUBMED]<\/a>[INFOTRIEVE]<\/a>[CROSSREF]<\/a>","journal-title":"Pharmacol Biochem Behav"},{"key":"E00004","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.bjp.0703496","volume":"130","author":"Duxon MS","year":"2000","unstructured":"Duxon, MS and Starr, KR and Upton, N. (2000) Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635 Br J Pharmacol<\/i>, 130, pp. 1713 - 1719. [PUBMED]<\/a>[INFOTRIEVE]<\/a>[CROSSREF]<\/a>","journal-title":"Br J Pharmacol"},{"key":"E00005","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0893-133X(02)00312-3","volume":"27","author":"Varty GB","year":"2002","unstructured":"Varty, GB and Morgan, CA and Cohen-Williams, ME and Coffin, VL and Carey, GJ. (2002) The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation Neuropsychopharmacology<\/i>, 27, pp. 357 - 370. [PUBMED]<\/a>[INFOTRIEVE]<\/a>[CROSSREF]<\/a>","journal-title":"Neuropsychopharmacology"},{"key":"E00006","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"Hamilton M","year":"1959","unstructured":"Hamilton, M. (1959) The assessment of anxiety states by rating Br J Med Psychol<\/i>, 32, pp. 50 - 55. [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"Br J Med Psychol"},{"key":"E00007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"Hamilton M","year":"1960","unstructured":"Hamilton, M. (1960) A rating scale for depression J Neurol Neurosurg Psychiatry<\/i>, 23, pp. 56 - 62. [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"E00008","first-page":"35","volume":"63","author":"Culpepper L","year":"2002","unstructured":"Culpepper, L. (2002) Generalized anxiety disorder in primary care: Emerging issues in management and treatment J Clin Psychiatry<\/i>, 63(Suppl 8), pp. 35 - 42. [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"J Clin Psychiatry"},{"key":"E00009","first-page":"11","volume":"63","author":"Keller MB","year":"2002","unstructured":"Keller, MB. (2002) The long-term clinical course of generalized anxiety disorder J Clin Psychiatry<\/i>, 63(Suppl 8), pp. 11 - 16. [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"J Clin Psychiatry"},{"key":"E00010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0006-3223(01)01145-3","volume":"50","author":"Owens MJ","year":"2001","unstructured":"Owens, MJ and Knight, DL and Nemeroff, CB. (2001) Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine Biol Psychiatry<\/i>, 50, pp. 345 - 350. [PUBMED]<\/a>[INFOTRIEVE]<\/a>[CROSSREF]<\/a>","journal-title":"Biol Psychiatry"},{"key":"E00011","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0014-2999(03)01376-1","volume":"464","author":"S\u00e1nchez C","year":"2003","unstructured":"S\u00e1nchez, C. (2003) R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalization model Eur J Pharmcol<\/i>, 464, pp. 155 - 158. [CROSSREF]<\/a>","journal-title":"Eur J Pharmcol"},{"key":"E00012","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00213-002-1364-z","volume":"167","author":"S\u00e1nchez C","year":"2003","unstructured":"S\u00e1nchez, C and Bergqvist, PB and Brennum, LT and Gupta, S and Hogg, S and Larsen, A and Wiborg, O. (2003) Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities Psychopharmacology (Berl)<\/i>, 167, pp. 353 - 362.","journal-title":"Psychopharmacology (Berl)"},{"key":"E00013","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0091-3057(03)00165-5","volume":"75","author":"S\u00e1nchez C","year":"2003","unstructured":"S\u00e1nchez, C and Gruca, P and Bien, E and Papp, M. (2003) R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety Pharmacol Biochem Behav<\/i>, 75, pp. 903 - 907. [CROSSREF]<\/a>","journal-title":"Pharmacol Biochem Behav"},{"key":"E00014","author":"GoodmanWK","year":"2003","unstructured":"Goodman, WK and Bose, A and Wang, Q.(2003) Escitalopram 10 mg\/day is effective in the treatment of generalized anxiety disorder. In Poster presented at: 156th Annual Meeting of the American Psychiatric Association; May 17\u201322<\/i>. . San Fransciso CA"},{"key":"E00015","first-page":"69","volume":"18","author":"Lipman RS","year":"1982","unstructured":"Lipman, RS. (1982) Differentiating anxiety and depression in anxiety disorders: use of rating scales Psychopharmacol Bull<\/i>, 18, pp. 69 - 77. [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"Psychopharmacol Bull"},{"key":"E00016","first-page":"35","author":"LipmanRS","year":"2001","unstructured":"Lipman, RS.(2001) Covi Anxiety Scale (1982).. In Rating Scales in Mental Health<\/i>. ( pp. 35 - 58 ). Hudson OH: Lexi-Comp.."},{"key":"E00017","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00005053-196901000-00010","volume":"148","author":"Raskin A","year":"1969","unstructured":"Raskin, A and Schulterbrandt, J and Reatig, N and McKeon, JJ. (1969) Replication of factors of psychopathology in interview, ward behavior, and self report ratings of hospitalized depressives J Nerv Ment Dis<\/i>, 148, pp. 87 - 96. [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"J Nerv Ment Dis"},{"key":"E00018","first-page":"217","author":"GuyW","year":"1976","unstructured":"Guy, W.(1976) ECDEU Assessment Manual for Psychopharmacology<\/i>. Rockville MD: US GPO."},{"key":"E00019","first-page":"321","volume":"29","author":"Endicott J","year":"1993","unstructured":"Endicott, J and Nee, J and Harrision, W and Blumenthal, R. (1993) Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure Psychopharmacol Bull<\/i>, 29, pp. 321 - 326. [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"Psychopharmacol Bull"},{"key":"E00020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4088\/JCP.v63n0414","volume":"63","author":"Clayton AH","year":"2002","unstructured":"Clayton, AH and Pradko, JF and Croft, HA and Montano, CB and Leadbetter, RA and Bolden-Watson, C and Bass, KI and Donahue, RM and Jamerson, BD and Metz, A. (2002) Prevalence of sexual dysfunction among newer antidepressants J Clin Psychiatry<\/i>, 63, pp. 357 - 366. [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"J Clin Psychiatry"},{"key":"E00021","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1345\/aph.1A195","volume":"36","author":"Gregorian RS","year":"2002","unstructured":"Gregorian, RS and Golden, KA and Bahce, A and Goodman, C and Kwong, WJ and Khan, ZM. (2002) Antidepressant-induced sexual dysfunction Ann Pharmacother<\/i>, 36, pp. 1577 - 1589. [PUBMED]<\/a>[INFOTRIEVE]<\/a>[CROSSREF]<\/a>","journal-title":"Ann Pharmacother"},{"key":"E00022","year":"2002","unstructured":"(2002) Lexapro (escitalopram oxalate) package insert<\/i>. New York : Forest Laboratories."},{"key":"E00023","author":"Paxil (paroxetine hydrochloride) package insert","year":"2003","unstructured":"Paxil (paroxetine hydrochloride) package insert.(2003) Research Triangle Park<\/i>. GlaxoSmithKline."},{"key":"E00024","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3810\/pgm.2003.08.1474","volume":"114","author":"Ditto KE","year":"2003","unstructured":"Ditto, KE. (2003) SSRI discontinuation syndrome. Awareness as an approach to prevention Postgrad Med<\/i>, 114, pp. 79 - 84. [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"Postgrad Med"},{"key":"E00025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0006-3223(98)00126-7","volume":"44","author":"Rosenbaum JF","year":"1998","unstructured":"Rosenbaum, JF and Fava, M and Hoog, SL and Ascroft, RC and Krebs, WB. (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial Biol Psychiatry<\/i>, 44, pp. 77 - 87. [PUBMED]<\/a>[INFOTRIEVE]<\/a>[CROSSREF]<\/a>","journal-title":"Biol Psychiatry"},{"key":"E00026","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF02850015","volume":"19","author":"Tamam L","year":"2002","unstructured":"Tamam, L and Ozpoyraz, N. (2002) Selective serotonin reuptake inhibitor discontinuation syndrome: a review Adv Ther<\/i>, 19, pp. 17 - 26. [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"Adv Ther"},{"key":"E00027","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/da.10146","volume":"19","author":"Davidson JRT","year":"2004","unstructured":"Davidson, JRT and Bose, A and Korotzer, A and Zheng, H. (2004) Escitalopram in the treatment of generalized anxiety disorder: a double-blind, placebo controlled, flexible dose study Depress Anxiety<\/i>, 19, pp. 234 - 240. [PUBMED]<\/a>[INFOTRIEVE]<\/a>[CROSSREF]<\/a>","journal-title":"Depress Anxiety"},{"key":"E00028","author":"Davidson JRT","year":"2003","unstructured":"Davidson, JRT and Bose, A and Wang, Q. (2003) Escitalopram in the long-term treatment of generalized anxiety disorder Poster presented at: 16th Congress of the European College of Neuropsychopharmacolgoy; September 20\u201324<\/i>.","journal-title":"Poster presented at: 16th Congress of the European College of Neuropsychopharmacolgoy; September 20\u201324"},{"key":"E00029","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4088\/JCP.v62n0508","volume":"62","author":"Pollack MH","year":"2001","unstructured":"Pollack, MH and Zaninelli, R and Goddard, A and McCafferty, JP and Bellew, KM and Burnham, DB and Iyengar, MK. (2001) Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible dose trial J Clin Psychiatry<\/i>, 62, pp. 350 - 357. Erratum in: J Clin Psychiatry 2001; 62:658 [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"J Clin Psychiatry"},{"key":"E00030","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4088\/JCP.v61n1109","volume":"61","author":"Fava M","year":"2000","unstructured":"Fava, M and Judge, R and Hoog, SL and Nilsson, ME and Koke, SC. (2000) Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment J Clin Psychiatry<\/i>, 61, pp. 863 - 867. [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"J Clin Psychiatry"},{"key":"E00031","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3928\/0279-3695-20020101-09","volume":"40","author":"Finfgeld DL","year":"2002","unstructured":"Finfgeld, DL. (2002) Selective serotonin reuptake inhibitor. Discontinuation syndrome J Psychosoc Nurs Ment Health Serv<\/i>, 40, pp. 14 - 18. [PUBMED]<\/a>[INFOTRIEVE]<\/a>","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"E00032","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00002826-200003000-00006","volume":"23","author":"Harvey BH","year":"2000","unstructured":"Harvey, BH and Bouwer, CD. (2000) Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors Clin Neuropharmacol<\/i>, 23, pp. 90 - 97. [PUBMED]<\/a>[INFOTRIEVE]<\/a>[CROSSREF]<\/a>","journal-title":"Clin Neuropharmacol"}],"container-title":["Annals of Clinical Psychiatry"],"original-title":[],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T11:15:52Z","timestamp":1757502952000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.portico.org\/Portico\/article?article=pf1m9k69pq"},"secondary":[{"URL":"http:\/\/triggered.stanford.clockss.org\/ServeContent?rft_id=info:doi\/10.1080\/10401230590932326","label":"CLOCKSS_SU"},{"URL":"http:\/\/triggered.edina.clockss.org\/ServeContent?rft_id=info:doi\/10.1080\/10401230590932326","label":"CLOCKSS_EDINA"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,4]]}},"URL":"https:\/\/doi.org\/10.1080\/10401230590932326","relation":{},"ISSN":["1040-1237","1547-3325"],"issn-type":[{"value":"1040-1237","type":"print"},{"value":"1547-3325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}